Vanguard Asset Management
TXG icon

Vanguard Asset Management’s 10x Genomics TXG Stock Holding History

Vanguard Asset Management’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.83M Buy
99,832
+171
+0.2% +$4.48K ﹤0.01% 1199
2026
Q1 		$2.12M Buy
+99,661
New +$1.99M ﹤0.01% 1436

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Asset Management's TXG Position: Q2 2026 in Review

Vanguard Asset Management increased its 10x Genomics (TXG) stake by 0.17% in Q2 2026, buying an estimated $4.48K and bringing the position to 99,832 shares worth $3.83M. The position accounts for ﹤0.01% of the portfolio, ranked #1199.

Vanguard Asset Management first reported a position in TXG in Q1 2026 and has held it in 2 quarters since. 380 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Vanguard Asset Management held 99,832 shares of 10x Genomics worth $3.83M as of Q2 2026.
  • Vanguard Asset Management bought 171 10x Genomics shares in Q2 2026, an estimated $4.48K.
  • 10x Genomics made up ﹤0.01% of Vanguard Asset Management's portfolio in Q2 2026, its #1199 holding.
  • Vanguard Asset Management first reported a position in 10x Genomics in Q1 2026 and has held it in 2 quarters since.
  • 380 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.